Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Comment by C10H12N2on Apr 07, 2023 8:55am
91 Views
Post# 35384486

RE:RE:RE:HUGE NEWS : $4 MILLION IN FUNDING FROM NRC

RE:RE:RE:HUGE NEWS : $4 MILLION IN FUNDING FROM NRCThere was a 100% chance you would bite the hook this morning with a reply. The early bird always catches the worm. If one follows your cut and paste posts you always deem to be "Due Diligence" one would think Arch would have reached a Billion Dollar market cap by now. It would appear that through all your ranting from one year to the next has not been the intended outcome. I assume the overall market is smart enough to know the difference between the rhetoric and reality. Keep plugging away with your bogus statistics about a level of success  However, your cakewalk talk has yet to bear any fruit but it does sound like a recipe for a fruitcake. I'm next expecting the usual suspects to crawl out of their crevices to your help.
<< Previous
Bullboard Posts
Next >>